Clinical Trials Logo

Filter by:
NCT ID: NCT04276909 Withdrawn - Pancreatic Cancer Clinical Trials

Feasibility Study of LUM Imaging System for Pancreatic Cancer

Start date: January 2026
Phase: N/A
Study type: Interventional

This single-site, non-randomized, open-label study to assess the initial safety and efficacy of the LUM Imaging System for detection of primary pancreatic cancer and peritoneal invasion from primary pancreatic cancer during surgery. In this feasibility study, the tumor detection algorithm will be developed for this indication.

NCT ID: NCT04276597 Withdrawn - Clinical trials for Neuroendocrine Tumors

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

PUTNET
Start date: March 4, 2020
Phase: Phase 2
Study type: Interventional

Determine the safety and effectiveness of Lu-177 DOTATOC in adult subjects with somatostatin receptor-expressing Pulmonary, Pheochromocytoma, Paraganglioma, Unknown primary, and Thymus neuroendocrine tumors or any other non-.GEP-NET. The treatment regimen will consist of 4 doses of 200 (±10%) mCi 177Lu-DOTATOC administered at 8+/- 1-week intervals.

NCT ID: NCT04276454 Withdrawn - Clinical trials for Head and Neck Cancer

Lymphedema Treatment in Head and Neck Cancer Patients

Start date: April 23, 2020
Phase: N/A
Study type: Interventional

The purpose of this research is to evaluate the result of treatment for neck lymphedema on throat pressure in patients who have received radiation therapy for head and neck cancer.

NCT ID: NCT04275752 Withdrawn - Kidney Transplant Clinical Trials

Exercise Intervention on Frailty After Kidney Transplantation

Start date: February 1, 2022
Phase: N/A
Study type: Interventional

Researchers are trying to determine if exercise will improve health and strength in kidney transplant patients.

NCT ID: NCT04273919 Withdrawn - Clinical trials for Back Pain Lower Back Chronic

Virtual Reality for the Treatment of Chronic Low Back Pain

VR
Start date: August 1, 2020
Phase: N/A
Study type: Interventional

Chronic low back pain is highly prevalent in US adults and is a major cause of missed work days and disability. While several treatment options exist, chronic opioids are commonly used for these conditions even though there are limited data supporting efficacy, and clear evidence of harm associated with chronic opioid administration. Virtual reality has been proposed as a treatment option that may lead to decreased pain and improved physical functioning, while avoiding the harms associated with medication management. This study is intended to obtain preliminary safety and efficacy data to guide the design of a larger clinical trial.

NCT ID: NCT04272645 Withdrawn - Prostate Cancer Clinical Trials

Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

Start date: October 2020
Phase: Phase 2
Study type: Interventional

This research is studying two experimental drugs, abemaciclib and atezolizumab, alone and in combination with each other, to learn about the safety and effectiveness of these treatments and their side effects. This is an investigational study treatment for adult men with metastatic castrate resistant prostate cancer (mCRPC) who have progressive disease despite previous treatment with androgen deprivation therapy (ADT). One group of men (men without a genetic mutation called "CDK12 loss") will receive abemaciclib therapy alone. Two other groups of men (men with CDK12 loss in one group and men without CDK12 loss in the other) will receive the combination of abemaciclib and atezolizumab. Another group of men with CDK12 loss will receive atezolizumab therapy alone.

NCT ID: NCT04270929 Withdrawn - Clinical trials for Pancreatic Adenocarcinoma

Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma

PANC-001
Start date: December 23, 2019
Phase: Phase 1
Study type: Interventional

This is an open label, single institution, dose-escalation phase 1 study designed to assess the feasibility, safety, and efficacy of oxaliplatin administered via Pancreatic Retrograde Venous Infusion (PRVI) using Pressure Enabled Drug Delivery (PEDD) technology. Oxaliplatin PEDD-PRVI is administered with systemic FOLFIRI followed by FOLFIRINOX therapy for the treatment of patients with unresectable or metastatic pancreatic adenocarcinoma.

NCT ID: NCT04269317 Withdrawn - Scars Clinical Trials

Clinical Study to Evaluate the Safety and Effectiveness of the Treatment With Tixel C on Acne Scars

Start date: March 1, 2020
Phase: N/A
Study type: Interventional

The purpose of this research is to evaluate the safety and effectiveness of the Tixel C device for the treatment of acne scars, for improvement in the appearance of surface texture.

NCT ID: NCT04268693 Withdrawn - Clinical trials for Triple Negative Breast Cancer

Bisphenol and Phthalate Exposures in Triple Negative Breast Cancer

EDC-TNBC
Start date: September 2022
Phase:
Study type: Observational

In this observational pilot study urine samples will be collected from women receiving neoadjuvant chemotherapy with doxorubicin for triple negative breast cancer to determine whether: 1) exposures bisphenol and phthalate levels change over the course of neoadjuvant chemotherapy, and 2) levels differ between black women and those of other racial groups. The hypothesis is that bisphenol and phthalate levels will be similar to those of the general US female population at the time of diagnosis, however levels will increase during treatment due to exposure to plastics in the medical setting. The investigators also hypothesize that because of differences in personal care product use, black women may have higher urinary levels of bisphenols and phthalates prior to starting chemotherapy.

NCT ID: NCT04268160 Withdrawn - Aortic Stenosis Clinical Trials

GPx Activity in Subjects With Aortic Stenosis Undergoing TAVR

Start date: November 2020
Phase:
Study type: Observational

The aim of this project is to investigate the association of glutathione peroxidase (GPx) and severe aortic stenosis (AS), as well as the impact of transcatheter aortic valve replacement (TAVR) on GPx activity post-procedure. The burden of oxidative stress will be determined by the measurement of GPx, superoxide dismutase (SOD) and lipoprotein A (Lp(a)). We hypothesize GPx activity is reduced in participants with severe AS vs control groups and GPx activity is to increase after TAVR is performed.